indazoles has been researched along with bilirubin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karaczyn, A; Keppler, BK; Kozłowski, H; Trynda-Lemiesz, L | 1 |
| Chang, YS; Lee, M; Park, WS | 1 |
| Baker, KL; Cardon, LR; Chen, EP; Chen, M; Ellens, HE; Huang, L; Mooser, VE; Pandite, L; Reck, BH; Spraggs, CF; Xu, CF; Xue, Z | 1 |
| Guo, F; Khamly, K; Michael, M; Olszanski, AJ; Pierce, KJ; Vlahovic, G | 1 |
| Bytzek, AK; Dömötör, O; Enyedy, EA; Hartinger, CG; Keppler, BK; Kiss, T | 1 |
| Carpenter, C; Choueiri, TK; Deen, KC; Johnson, T; Motzer, RJ; Pandite, LN; Xu, CF; Xue, Z | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Chan, AWH; Chan, SL; Chong, CCN; Hui, EP; Koh, J; Lai, PBS; Li, L; Mo, F; Mok, TSK; Yeo, W; Yu, SCH | 1 |
| Afsar, B; Armagan, B; Bilgetekin, I; Cetin, B; Demirci, U; Gulbahar, O; Gumusay, O; Ozet, A; Uner, A; Yılmaz, GE | 1 |
| Chin, S; Choi, JW; Kim, SG; Kim, YS; Yoo, JJ | 1 |
2 trial(s) available for indazoles and bilirubin
| Article | Year |
|---|---|
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bilirubin; Creatinine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Patient Selection; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2010 |
A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Agents; Axitinib; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome; Tumor Burden | 2017 |
8 other study(ies) available for indazoles and bilirubin
| Article | Year |
|---|---|
Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III).
Topics: Bilirubin; Chromatography; Circular Dichroism; Dextrans; Heme; Humans; Indazoles; Models, Chemical; Organometallic Compounds; Protein Binding; Protein Conformation; Serum Albumin; Spectrometry, Fluorescence; Spectrophotometry; Ultraviolet Rays; Warfarin | 2000 |
Effect of 7-nitroindazole on bilirubin-induced changes in brain cell membrane function and energy metabolism in newborn piglets.
Topics: Animals; Animals, Newborn; Bilirubin; Blood Glucose; Cell Membrane; Cerebral Cortex; Drug Interactions; Energy Metabolism; Enzyme Inhibitors; Glucose; Indazoles; Kernicterus; Lactic Acid; Lipid Peroxidation; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Random Allocation; Sodium-Potassium-Exchanging ATPase; Statistics, Nonparametric; Swine | 2002 |
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Bilirubin; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kidney Neoplasms; Liver; Male; Middle Aged; Nephrectomy; Polymorphism, Genetic; Pyrimidines; Sulfonamides | 2010 |
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Topics: Antineoplastic Agents; Bilirubin; Binding, Competitive; Heme; Humans; Indazoles; Organometallic Compounds; Ruthenium; Ruthenium Compounds; Serum Albumin; Spectrometry, Fluorescence | 2013 |
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
Topics: Bilirubin; Biomarkers, Pharmacological; Genetic Association Studies; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Indoles; Liver; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2013 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Bilirubin; Blood Chemical Analysis; Blood Glucose; Chemical and Drug Induced Liver Injury; Fatty Liver; Hemosiderin; Indazoles; Kupffer Cells; Liver; Male; Pyrimidines; Rats; Rats, Wistar; Sulfonamides | 2018 |
Pazopanib-induced severe acute liver injury: A case report.
Topics: Bilirubin; Biopsy; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Hepatitis B; Humans; Indazoles; Jaundice; Kidney Neoplasms; Middle Aged; Nausea; Pyrimidines; Steroids; Sulfonamides; Tomography, X-Ray Computed; Ultrasonography; United States; Vomiting | 2021 |